F Morabito
Overview
Explore the profile of F Morabito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
212
Citations
826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martino E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, et al.
ESMO Open
. 2025 Jan;
10(2):104084.
PMID: 39778329
Background: Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large,...
2.
Reda G, Cassin R, Gentile M, Mauro F, Giannarelli D, Fattizzo B, et al.
Leukemia
. 2019 Jan;
33(6):1519-1522.
PMID: 30635629
No abstract available.
3.
Barisione G, Fabbi M, Cutrona G, De Cecco L, Zupo S, Leitinger B, et al.
Blood Cancer J
. 2017 Jan;
6(1):e513.
PMID: 28060374
No abstract available.
4.
Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, et al.
Leukemia
. 2017 Jan;
31(9):1894-1904.
PMID: 28053325
Chronic lymphocytic leukemia (CLL) clones are characterized by loss of a critical region in 13q14.3, (del(13)(q14)) involving the microRNA (miRNA) cluster miR-15a and miR-16-1. We have investigated the effects of...
5.
Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, et al.
Blood Cancer J
. 2016 Sep;
6(9):e468.
PMID: 27611921
Long non-coding RNAs (lncRNAs) represent a novel class of functional RNA molecules with an important emerging role in cancer. To elucidate their potential pathogenetic role in chronic lymphocytic leukemia (CLL),...
6.
Ferrarini M, Cutrona G, Neri A, Morabito F
Leuk Suppl
. 2016 May;
1(Suppl 2):S29-30.
PMID: 27175240
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for...
7.
Martino M, Tripepi G, Messina G, Vincelli I, Console G, Recchia A, et al.
Bone Marrow Transplant
. 2016 Apr;
51(9):1197-203.
PMID: 27088375
This phase II trial evaluates, for the first time, the safety and efficacy of bendamustine plus high-dose melphalan (HDM) as a conditioning regimen before the second autologous stem cell transplantation...
8.
Larocca A, Bringhen S, Petrucci M, Oliva S, Falcone A, Caravita T, et al.
Leukemia
. 2016 Feb;
30(6):1320-6.
PMID: 26898189
This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus oral prednisone (VP, N=51)...
9.
Gentile M, Shanafelt T, Cutrona G, Molica S, Tripepi G, Alvarez I, et al.
Leukemia
. 2015 Dec;
30(6):1440-3.
PMID: 26648537
No abstract available.
10.
Mauro F, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, et al.
Leukemia
. 2015 Feb;
29(6):1360-5.
PMID: 25650091
In order to evaluate the predictive value of positron emission tomography-computed tomography (PET/CT) in discriminating the presence of a Richter's syndrome (RS) or a second malignancy (SM), as well as...